医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Cover-More Appoints Head of Sales for USA and Canada Travel Insurance Operations

2016年06月29日 PM10:00
このエントリーをはてなブックマークに追加


 

SYDNEY

Cover-More Group (ASX:CVO), a specialist, integrated travel insurance and medical assistance provider, has appointed Mark Linton as Head of Sales for USA and Canada.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160629005594/en/

Mark Linton Cover-More Head of Sales US & Canada (Photo: Business Wire)

Mark Linton Cover-More Head of Sales US & Canada (Photo: Business Wire)

His appointment follows Cover-More’s announcement that their executive Carole Tokody was relocating to New York as CEO, US & Canada and Global Direct to lead their North America and northern hemisphere expansion.

Mark will report directly to Carole Tokody and will be responsible for the sales of travel insurance and ancillary products and services in the US and Canadian markets. Mark’s significant experience includes 15 years with RBC Insurance where he managed a national sales team, maintaining and acquiring numerous large national and regional accounts.

About Cover-More Group

Cover-More Group Limited is a specialist and integrated travel insurance, medical assistance and employee assistance provider. The group listed on the Australian Securities Exchange (ASX) in 2013. Cover-More has the leading market position in Australia—with an approximate 40% share of the national travel insurance market and a growing footprint in India and China as well as a presence in Malaysia, Singapore, New Zealand and the United Kingdom and now the United States.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160629005594/en/

CONTACT

For more information:
Pilot PR for Cover-More Group
Limited

Angela Cross, +61412 929 397
angela@pilotpr.com.au

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • アスターDMヘルスケア、25万米ドル相当の世界看護賞を発表
  • Prestige BioPharma Enters MOU with Busan City for Establishment of its R&D Centre in Busan, South Korea
  • Celltrion Confirms Neutralising Potency Against Emerging SARS-CoV-2 Variants With Anti-COVID-19 Monoclonal Antibody Treatment regdanvimab (CT-P59)
  • InnoCare Announces Approval of Clinical Trial of TYK2 Inhibitor ICP-332 in China
  • 患者安全运动基金会公布参加首届医疗安全研究员项目五人名单